AG
TXMD icon

Advisor Group’s TherapeuticsMD TXMD Stock Holding History

Advisor Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$94K Buy
779
+56
+8% +$8.05K ﹤0.01% 2985
2019
Q3 		$131K Buy
723
+444
+159% +$62.6K ﹤0.01% 2680
2019
Q2 		$36K Buy
279
+118
+73% +$21.2K ﹤0.01% 3584
2019
Q1 		$38K Buy
161
+100
+164% +$26.5K ﹤0.01% 3576
2018
Q4 		$11K Buy
61
+8
+15% +$1.95K ﹤0.01% 4157
2018
Q3 		$17K Buy
53
+34
+179% +$10.4K ﹤0.01% 3991
2018
Q2 		$6K Sell
19
-32
-63% -$9.78K ﹤0.01% 4320
2018
Q1 		$12K Sell
51
-36
-41% -$10.1K ﹤0.01% 3985
2017
Q4 		$27K Sell
87
-3
-3% -$835 ﹤0.01% 3517
2017
Q3 		$25K Sell
90
-24
-21% -$6.94K ﹤0.01% 3438
2017
Q2 		$30K Sell
114
-81
-42% -$20.3K ﹤0.01% 3209
2017
Q1 		$70K Sell
195
-16
-8% -$4.95K ﹤0.01% 2437
2016
Q4 		$61K Buy
211
+25
+13% +$7.75K ﹤0.01% 2453
2016
Q3 		$64K Sell
186
-173
-48% -$63.2K ﹤0.01% 2327
2016
Q2 		$152K Buy
+359
New +$148K ﹤0.01% 1652

Other funds holding TXMD

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advisor Group's TXMD Position: Q4 2019 in Review

Advisor Group increased its TherapeuticsMD (TXMD) stake by 7.7% in Q4 2019, buying an estimated $8.05K and bringing the position to 779 shares worth $94K. The position accounts for ﹤0.01% of the portfolio, ranked #2985.

Advisor Group first reported a position in TXMD in Q2 2016 and has held it in 15 quarters since. The position peaked at $152K in Q2 2016. 168 funds tracked by Wall St. Rank hold TXMD as of Q4 2019.

  • Advisor Group held 779 shares of TherapeuticsMD worth $94K as of Q4 2019.
  • Advisor Group bought 56 TherapeuticsMD shares in Q4 2019, an estimated $8.05K.
  • TherapeuticsMD made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2985 holding.
  • Advisor Group first reported a position in TherapeuticsMD in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's TherapeuticsMD position peaked at $152K in Q2 2016.
  • 168 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.